Our goal is to cure cancer.
Our strategy is based on developing novel small molecule drugs that simultaneously target multiple cancer promoting pathways with specific delivery systems to treat recalcitrant cancers including pancreatic and liver cancer.
Since we’ve been in business, we have been striving to build a pipeline of anti-cancer drugs. We have one drug candidate, AP-001, on which we are doing pre-clinical testing. We expect that first-in-man Phase 1 clinical trials will begin in late 2018. We have several other drug candidates and drug delivery systems in the pipeline.
Stephen J. Pandol, MD
President, Board of Directors Member & Co-Founder
Dr. Pandol has over 35 years experience in studying pancreatic diseases, especially pancreatitis and pancreatic cancer. Dr. Pandol’s undergraduate degree is from UC Davis and his medical degree from St. Louis University School of Medicine. He is the author of numerous peer-reviewed publications and is a reviewer, editorial board member and editor of number journals.
Ramachandran Murali, PhD
Dr. Murali is the Director of the Molecular Therapeutics Core and Associate Professor at Cedars-Sinai Medical Center. He has focused on the molecular basis of cancer metastasis and identification of therapeutic strategies to limit the recurrence of cancer. His PhD is from the University of Madras.
Terrance Bruggeman, MBA
CEO & Board of Directors Member
Terry Bruggeman is an experienced CEO who has led four life sciences companies, including two drug discovery firms, to successful exits since 1996. Previously he served in a variety of financial roles and was CEO of several technology companies. His undergraduate degree is from the University of Notre Dame and he attended the MBA program at the Booth School of Business University of Chicago.
Mouad Edderkaoui, PhD
CSO, Board of Directors Member & Co-Founder
Dr. Edderkaoui has over 15 years experience in studying mechanisms of cancer development and metastasis. He has a Master Degree from the Catholic University of Louvain in Belgium and a PhD in Cellular and Molecular Biology from the Ernst-Moritz-Arndt University of Greifswald, Germany. Dr. Edderkaoui has authored over 25 articles and book chapters. He serves as Associate Editor and reviewer for many scientific journals.
Fred Kohn, PhD
Dr. Kohn is an independent consultant specializing in pharmacology. He has held positions with Paramount, Pfizer, MicroIslet and SkyePharma. His undergraduate degree in Biology is from the University of Illinois and his PHD in Pharmacology is from the University of Minnesota.
David Ryckman, PhD
Dr. Ryckman is an independent consultant specializing in CMC. He was previously VP of Chemistry and Pharmaceutical Operations for a number of drug discovery companies including Senhwa, Cyclene, Myogen/Gilead, Pathogenesis, Gensia and SmithKline Beecham. His undergraduate degree in Chemistry is from UCLA, Master degree from California State University, Northridge and PhD in Chemistry from UCLA.
Aida Habtezion, MD
Dr. Habtezion is an Associate Professor of Medicine (Gastroenterology and Hepatology) at Stanford University. Her research interests include gastroenterology and inflammatory bowel disease. She received her MD from McMaster University.
Scientific Advisory Board
David Kramer, MBA
David Kramer has had CFO experience in four life science companies, including Gen-Probe, Inc., Chugai Biopharmaceuticals, Inc, Anadys Pharmaceuticals, Inc., and Somanta, Inc. He earned a B.A. from Yale and an M.B.A. from Harvard Business School.
David Brenner, MD
Dr. Brenner is Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of California, San Diego. In this role, he leads the School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California, San Diego, and UC San Diego Health.
Grace Furman, PhD
Dr. Furman is the President of Paracelsus, Inc. Previously she has lead the toxicology and regulatory safety assessments at Pfizer Global R&D, DepoTech, and Procter & Gamble. Her undergraduate degree and PhD in Toxicology are from Northeastern University, She holds a Diplomate from the American Board of Toxicology.
Linda Strause, PhD
Dr. Strause is Principal and Founder of Strategic Clinical Consultants. She has more than 25 years of expertise in global clinical operations and clinical development, with an emphasis in oncology, critical care, and ethical considerations for subjects with life-threatening diseases. She assists her clients, primarily virtual and small biopharma companies, in the conduct of clinical trials. Her undergraduate degree is from UC San Diego and her PhD from UC Santa Barbara in Neurophysiology..